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Advantages of adjusting the initial dose of intravenous calcitriol roid function [8]. Other limitations revealed by this study
according to PTH levels. which would have significant repercussions in clinical
Background. To assess the usefulness of starting calcitriol management include the need to adopt more homoge-therapy with a dose proportional to the degree of hyperpara-
nous criteria relating to what the exact initial dose ofthyroidism, 141 patients from 28 centers were treated with
vitamin D metabolites should be, as well as the need tointravenous calcitriol for 6 months. The aim was to achieve a
final PTH between 125 and 250 pg/mL. Patients with serum quickly determine which patients do or do not respond
PTH 250 pg/mL were included in the study and divided into to the treatment.
4 groups according to baseline PTH levels.
Guidelines from the Spanish Society of NephrologyMethods. The study was completed by 100 patients, a third
[10] for the clinical management of renal osteodystrophyof which were treated strictly according to the protocol, labeled
“compliants”; thus, calcitriol was started according to baseline have reflected these results and transformed them into
PTH levels. Two thirds of patients, labeled “noncompliants,” recommendations with the aim of improving the manage-
showed one or more violation in the dosage regimen. ment of renal osteodystrophy, such as the use of calcitriolResults. After 2 months of treatment with calcitriol, 59% of
in doses proportional to the severity of secondary hyper-the “compliants” and 35% of the “noncompliants” decreased
parathyroidism. The aim of this study was to assess thetheir PTH levels 40% (P  0.022), 70%, and 49%, respec-
tively after 3 months of treatment. After 3 months of treatment, effectiveness of calcitriol administered in doses propor-
67% of the “compliants” reached the target (PTH 125 to 250 tional to the degree of secondary hyperparathyroidism
pg/mL) in contrast with 23% of the “noncompliants” (P 
and also to evaluate the adverse events found in using0.001). The number of hypercalcemic and hyperphosphatemic
this strategy.episodes was significantly lower in the “compliants” group (P
0.006).
Conclusion. These results demonstrate several advantages
METHODSwhen calcitriol therapy is started with a dose proportional to
the severity of hyperparathyroidism. The study was carried out on 141 dialysis patients
treated in 28 hemodialysis centers in Spain, 41 (29%) of
which did not finish the study due to the following causes:
Throughout recent years, knowledge of the factors 25 due to incomplete protocol; 3 due to transplantation;
and mechanisms that regulate bone metabolism, as well 3 due to excessive suppression of parathyroid function;
as the management of bone metabolic disorders of 4 due to repeated hyperphosphatemia; 2 due to death
chronic renal failure have improved [1–4]. In spite of by cardiovascular events; 1 due to change of residence;
these advances, limitations still exist [5]. Many of these
1 due to sepsis; 1 due to cerebral hemorrhage; and 1 due
limitations became clear in a Spanish multicenter study
to surgical parathyroidectomy.on renal osteodystrophy recently carried out [6–9]. Some
Of the 100 patients who completed the study, 42%of the resulting problems were unforeseen, but were, at
were women and 58% were men (mean age 59  16the same time, easy to correct, such as the necessity to
years) with a mean time on dialysis of 52  57 months.start the treatment with vitamin D metabolites early,
The most frequent calcium concentration used in theand also to finish such treatment as soon as possible in
dialysate was 2.5 mEq/L (74%).order to avoid the excessive suppression of the parathy-
The initial criterion for inclusion in the study, and for
the subsequent re-incorporation into the study after a
Key words: parathyroid hormone, hyperparathyroidism, hemodialysis. temporary suspension of treatment, was to have PTH
levels higher than 250 pg/mL. The aim was to achieve a 2003 by the International Society of Nephrology
S-79
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Table 1. Initial dose of calcitriol and frequency of measurement of different biochemical parameters according to the initial levels of PTH
Calcitriol dose 3 times Frequency of Frequency of Ca, P, Ca x P,
Group Initial PTH pg/mL per week lg PTH measurement and AP measurement
A  B 285–550 0.5–1 Monthly Fortnightly
C 550–750 1.5 Fortnightly Fortnightly
D 750 2 Fortnightly Fortnightly
final PTH between 125 and 250 pg/mL. The criteria for “compliants.” Thus, the terms “compliants” and “non-
compliants” do not qualify the behavior of the patient,being initially excluded were PTH levels lower than 250
pg/mL, serum calcium levels higher than 10.5 mg/dL, but instead refer fundamentally to the adherence to the
protocol by the nephrologists.serum phosphorus levels higher than 6 mg/dL, and a
calcium x phosphorus product (Ca x P) higher than 60. The statistical analysis was carried out using the statis-
tical package SPSS 8.0 for Windows (SPSS, Inc., Chicago,The criteria for having a temporary break from the study
were serum calcium levels higher than 11.2 mg/dL, serum IL, USA). The comparison between the beginning and
phosphorus levels higher than 6.5 mg/dL, and a Ca x P the end of treatment was carried out using the paired-
product higher than 70 mg2/dL2. samples Student t test. The association between categori-
Because starting the treatment with an initial dose of cal variables was analyzed using Pearson’s chi-squared
calcitriol proportional to the severity of hyperparathy- test. Changes were considered statistically significant if
roidism had been recommended, study groups were cre- P  0.05.
ated based on the PTH levels and the dose of calcitriol
administered following the clinical guidelines of the
RESULTSSpanish Society of Nephrology (Table 1).
One hundred patients completed the full 6 months ofThe frequency of biochemical analyses was pro-
the study; however, there were only 34 patients in whomgrammed according to the degree of hyperparathyroid-
the protocol was strictly implemented, while there wereism. Monthly and/or fortnightly controls of PTH and
66 patients in whom the protocol was implemented withfortnightly controls of the remaining parameters were
one or more violations (fundamentally due to calcitriolcarried out according to the severity of hyperparathy-
prescription not following the protocol). Groups A androidism (Table 1).
B were analyzed together.In all groups, the calcitriol dose was doubled if PTH
The mean initial PTH for all patients was 771  393dropped by less than 15%. In groups A, B, and C, the
pg/mL, with no differences between the “compliants”calcitriol dose was maintained if PTH dropped between
and “noncompliants” groups. The evolution of serum15% and 30% (except if alkaline phosphate fell by more
PTH after 3 months of treatment in the different groupsthan 25%, in which case the dose was reduced by 25%).
is shown in Figure 1. A decrease in the mean PTH wasIf PTH dropped between 30% and 60%, the dose was
observed in all patients, both in the “compliants” and thereduced by 25%, and finally, if PTH dropped by more
“noncompliants” groups. Nevertheless, in the individualthan 60%, the dose was halved. If a decrease of at least
analysis, it was verified that all the “compliants” except15% in PTH was not observed after 3 increases in the
calcitriol dose in groups A and B, or 2 increases in group one (2.9%) showed decreases in PTH, while in the “non-
compliants” there was no homogenous response. ThereC, the treatment was stopped.
In group D, if PTH fell between 15% and 45%, the were even increases in PTH in 7 patients (11%).
After a month of treatment with intravenous calcitriol,same dose was maintained (except if alkaline phosphate
fell by more than 25%, in which case the calcitriol dose 36% of the “compliants” and 24% of the “noncompli-
ants” decreased their PTH levels more than 40% (P was reduced by 25%), if PTH fell between 45% and
60% the dose was reduced by 25%, and if it fell by NS). After 2 months of treatment, the figures were 59%
and 35% (P  0.022), and after 3 months, 70% and 49%more than 60%, the calcitriol dose was halved. Only one
increase of dose was permitted in group D. If, by doing (P  0.046), respectively.
After 3 months of treatment, 67% of the “compliants”this, a decrease in PTH was not observed, treatment was
stopped. reached the objective of the study (PTH 125 to 250
pg/mL) in contrast with 23% of the “noncompliants”The patients were first treated following the above
scheme during 6 months. When the protocol was not (P  0.001) (Fig. 2). After 6 months of treatment, 82%
of the “compliants” and 14% of the “noncompliants”followed correctly on one or more occasions, the patients
were classified as “noncompliants,” compared to those reached the goal of the study (P  0.001).
The side effects of the treatment (hypercalcemia, hyper-who had correctly followed the protocol, classified as
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Fig. 2. Percentage of patients reaching the objective of the study (PTH
125 to 250 pg/mL) after 3 months of treatment in the different groups
of patients. *P  0.025 and **P  0.003, respectively.
mon practice was to initiate treatment with a calcitriol
dose independent from the initial serum PTH levels. In
fact, 77% of the patients received 1 g 3 times per week
as initial dose, and the dose was not initially adjusted
according to PTH levels [11, 12]. This commonly used
strategy requires a progressive increase of the dose,
which in turn increases the intestinal absorption of cal-
cium and phosphorous, frequently producing hypercal-
cemia and hyperphosphatemia before the desired PTH
response is obtained.
In order to obtain a more rapid response with fewer
side effects, the administration of calcitriol based on
baseline PTH levels has been recommended [13–15].
Fig. 1. Evolution of PTH after 3 months of treatment in the “compli- However, until this study, the published data referred
ants” and “noncompliants” in the 3 groups of patients. Gray boxes to the use of this strategy in severe and protracted cases
indicate the limits of PTH considered the goal of the study (125 to 250
of secondary hyperparathyroidism, but not in all formspg/mL). The percentage of PTH decrease is shown in parentheses. *P
0.002 compared with the initial PTH. of secondary hyperparathyroidism.
We believe that all forms of secondary hyperparathy-
roidism should be managed by dosing calcitriol according
to baseline PTH levels as it has been proposed by the
phosphoremia, or both) were noted in 25% of the “compli-
Spanish Society of Nephrology [10]. Throughout theants,” and in 57% of the “noncompliants” (P  0.006).
course of this study and after finishing the 6-month pe-
riod, we became aware of the high number of protocol
DISCUSSION violations. Furthermore, we realized that following, or
not strictly following, the protocol meant important dif-Moderate and severe cases of secondary hyperpara-
ferences in the final results. Thus, the patients were di-thyroidism still have a high percentage of treatment fail-
vided into 2 groups, the “compliants” and “noncompli-ure when using vitamin D metabolites. In a Spanish
ants,” with the aim of analyzing the differences in themulticenter study carried out on 10,724 dialysis patients,
results according to the adherence to the protocol fora lack of homogeneity was noted in the initial doses of
the doctor in charge of the study.intravenous calcitriol used according to the degree of
A decrease in the PTH levels was noted in the “compli-hyperparathyroidism [6]. Despite the fact that 71% of the
ants” as well as the “noncompliants,” but in the “compli-centers considered that the correct form of administering
ants,” the response was always better, more pronounced,calcitriol was to use a dose proportional to the severity
and much more homogeneous. The global analysisof secondary hyperparathyroidism, they did not use this
strategy from the beginning of treatment. The most com- showed that after 3 months, 67% of the 34 patients who
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